Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Market cap is the total market value to buy the whole company. It is equal to the share price times the number of Shares Outstanding (EOP). Stevanato Group SpA's share price for the quarter that ended in Jun. 2026 was €15.8. Stevanato Group SpA's Shares Outstanding (EOP) for the quarter that ended in Jun. 2026 was 273 Mil. Therefore, Stevanato Group SpA's market cap for the quarter that ended in Jun. 2026 was €4,315 Mil.
Stevanato Group SpA's quarterly market cap
declined
from Dec. 2025 (€4,750 Mil) to Mar. 2026 (€3,249 Mil) but then
increased
from Mar. 2026 (€3,249 Mil) to Jun. 2026 (€4,315 Mil).
Stevanato Group SpA's annual market cap
declined
from Dec. 2023 (€6,530 Mil) to Dec. 2024 (€5,567 Mil) and
declined
from Dec. 2024 (€5,567 Mil) to Dec. 2025 (€4,750 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Stevanato Group SpA's Enterprise Value for Today is €5,133 Mil.
Stevanato Group SpA (FRA:87N) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Stevanato Group SpA Market Cap Related Terms
Stevanato Group SpA Market Cap Historical Data
* Premium members only.
The historical data trend for Stevanato Group SpA's Market Cap can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, Stevanato Group SpA's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Stevanato Group SpA Market Cap vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Stevanato Group SpA's Market Cap distribution charts can be found below:
* The bar in red indicates where Stevanato Group SpA's Market Cap falls into.
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
Stevanato Group SpA's Market Cap for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Stevanato Group SpA (FRA:87N) has a Market Cap of €4,773 Mil as of Sep. 09, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Stevanato Group SpA and its competitors. According to the industry distribution chart, Stevanato Group SpA ranks #59 out of 859 companies in the Medical Devices & Instruments industry, placing it in the top 6.9%.
Is Stevanato Group SpA's Market Cap too high?
Stevanato Group SpA's current Market Cap is €4,773 Mil. Based on the distribution chart, Stevanato Group SpA ranks #59 out of 859 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Stevanato Group SpA has a GF Score™ of 87/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Stevanato Group SpA's Market Cap compare to MMED and TFX?
According to the Medical Devices & Instruments industry distribution chart, Stevanato Group SpA ranks #59 out of 859 companies for Market Cap. This places Stevanato Group SpA in the top 7% of its industry — outperforming the majority of peers. The industry median Market Cap is 121.83. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Medical Devices & Instruments company?
The median Market Cap among Medical Devices & Instruments companies is 121.83, based on 859 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Stevanato Group SpA and its competitors. For the Medical Devices & Instruments industry, the median Market Cap is 121.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Stevanato Group SpA's current Market Cap is €4,773 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Stevanato Group SpA stock overvalued right now?
Based on GuruFocus' analysis, Stevanato Group SpA (FRA:87N) is currently considered Modestly Undervalued. The stock's GF Value™ is €22.30, compared to a current price of €17.40 — trading 22% below its estimated fair value. The current Market Cap is €4,773 Mil. Stevanato Group SpA's overall GF Score™ is 87/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Stevanato Group SpA (FRA:87N), the current Market Cap is €4,773 Mil as of Sep. 09, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Stevanato Group SpA (FRA:87N) Overvalued in 2026?
Based on GuruFocus' analysis, Stevanato Group SpA stock appears to be undervalued.
The current stock price of €17.40 is trading 22% below its estimated GF Value™ of €22.30.
GuruFocus considers Stevanato Group SpA to be Modestly Undervalued.
Key valuation signals for FRA:87N:
Market Cap: €4,773 Mil
GF Value™: €22.30 vs. price of €17.40 (22% below fair value)
No single metric tells the full story. See the FRA:87N stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Stevanato Group SpA is a provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. It delivers an integrated, end-to-end portfolio of products, processes, and services that address customer needs across the entire drug life cycle including development, clinical, and commercial stages. It has two segments; Biopharmaceutical and Diagnostic Solutions which generates key revenue, includes all the products, processes and services developed and provided for the containment and delivery of pharmaceutical and biotechnology drugs and reagents, as well as the production of diagnostic consumables and its other segment is Engineering. Geographically, It derives its majority revenue from Europe, Middle East and Africa.
87GF Score
Get the complete analysis for FRA:87N
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:87N has been successfully added to your 
